Invasive Bladder Cancer

Oncology·MeSH: Neoplasm Metastasis

Prevalence

61.0 / 100K

Incidence

18.0 / 100K/yr

20 drugs in development·13 companies·1 clinical trial

Drug Pipeline by Phase

Approved(1)

Drug	Company
zusduri	UroGen Pharma Ltd. (URGN)

Phase 3(14)

Drug	Company
AU-011	Aura Biosciences, Inc. (AURA)
bacillus calmette guerin	GH Research PLC (GHRS)
bacillus calmette-guerin	ASTRAZENECA PLC (AZN)
bcg	ASTRAZENECA PLC (AZN)
BCG	ImmunityBio, Inc. (IBRX)
bcg + n-803	ImmunityBio, Inc. (IBRX)
cretostimogene	CG Oncology, Inc. (CGON)
enfortumab vedotin	ASTRAZENECA PLC (AZN)
N-803 and BCG	ImmunityBio, Inc. (IBRX)
nadofaragene firadenovec	VERTEX PHARMACEUTICALS INC / MA (VRTX)
Nadofaragene Firadenovec	Merus N.V. (MRUS)
Nadofaragene Firadenovec	Valneva SE (VALN)
Supportive care measures	Merck & Co., Inc. (MRK)
tara-002	Protara Therapeutics, Inc. (TARA)

Phase 2(2)

Drug	Company
cretostimogene grenadenorepvec	CG Oncology, Inc. (CGON)
lp-50	LIPELLA PHARMACEUTICALS INC. (LIPO)

Phase 1(2)

Drug	Company
ugn-201	UroGen Pharma Ltd. (URGN)
ugn-301	UroGen Pharma Ltd. (URGN)

Preclinical(1)

Drug	Company
uio-524	Transcode Therapeutics, Inc. (RNAZ)

BioSniper tracks 20 drugs in development for Invasive Bladder Cancer across 13 companies.

There are 1 clinical trial targeting Invasive Bladder Cancer tracked by BioSniper.

The estimated prevalence of Invasive Bladder Cancer is approximately 61.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.